CLIA compliance for colon cancer assay
MARSEILLE, France—HalioDx is now compliant under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for its Marseille-based full-service reference laboratory. As such, the company can now receive U.S. patient samples for Immunoscore Colon testing. The assay can be performed on FFPE samples with a turnaround time of 10 days and is available for oncologists and pathologists with colon cancer patients in select states within the U.S.
Vincent FERT, CEO of HalioDx, said “The availability of Immunoscore Colon under CLIA compliance is indeed an important step for serving U.S. patients and oncologists. We envision that Immunoscore will set a new prognostic standard in guiding the treatment of colon cancer as the test value is now supported by strong clinical data presented at ASCO 2017. HalioDx plans to further reinforce clinical utility of Immunoscore in colon cancer and also to expand to other types of cancer.”